Review article · 2023 · Open access

A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia

Shimeng Dong, Johannes Schneider‐Thoma, Irene Bighelli, Spyridon Siafis, Dongfang Wang, Angelika Burschinski, Kristina Schestag, Myrto T. Samara, Stefan Leucht

European Archives of Psychiatry and Clinical Neuroscience, 274(4), 917–928 · Published 1 August 2023 · DOI 10.1007/s00406-023-01654-2

Open PDFView at the publisherCite this paper

In brief

“A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia” is a 2023 review article by Shimeng Dong and 8 co-authors, published in European Archives of Psychiatry and Clinical Neuroscience. OpenAlex counts 78 citations as of 20 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at European Archives of Psychiatry and Clinical Neuroscience.

Citations
78
Most cited in
2026 (31)
Field-weighted impact
2.61
References
55
Authors
9

Abstract

OBJECTIVE: Clozapine is considered as the standard treatment for this subgroup, but the evidence is not unequivocal. There are several potential alternatives being used because of the possible adverse effects of clozapine. We aimed to examine the efficacy and adverse events of different antipsychotics in treatment-resistant schizophrenia by performing a network meta-analysis. METHODS: We searched the Cochrane Schizophrenia Group register for randomized-controlled trials (up to March 06, 2022) and MEDLINE (up to January 20, 2023). We included blinded and open studies and participants with a broad definition of treatment resistance. The primary outcome was overall symptoms of schizophrenia; secondary outcomes were response to treatment, positive and negative symptoms of schizophrenia, discontinuation, side effects, quality of life, and functioning. The study was registered in Open Science Framework ( https://osf.io/9nf2y/ ). RESULTS: We included 60 studies involving 6838 participants in the network meta-analysis. In the primary outcome, clozapine and olanzapine were more efficacious than risperidone, haloperidol, fluphenazine, sertindole, chlorpromazine, and quetiapine (range of mean SMDs, - 0.11 to - 0.48). The difference between clozapine and olanzapine was trivial and uncertain (SMD - 0.05, 95% CI, - 0.21 to 0.11). The result of other efficacy outcomes as well as subgroup and sensitivity analyses were consistent with the primary analysis. Clozapine and olanzapine were associated with more weight gain, and clozapine was associated with more sedation events compared to many other antipsychotics. CONCLUSIONS: Clozapine remains the gold standard for patients with treatment-resistant schizophrenia. Olanzapine seems to be second-best and could be tried before switching to clozapine.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Dong, S., Schneider‐Thoma, J., Bighelli, I., Siafis, S., Wang, D., Burschinski, A., Schestag, K., Samara, M. T., & Leucht, S. (2023). A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 274(4), 917–928. https://doi.org/10.1007/s00406-023-01654-2

MLA 9

Dong, Shimeng, et al. “A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia.” European Archives of Psychiatry and Clinical Neuroscience, vol. 274, no. 4, 2023, pp. 917–928. https://doi.org/10.1007/s00406-023-01654-2.

Chicago

Dong, Shimeng, Johannes Schneider‐Thoma, Irene Bighelli, Spyridon Siafis, Dongfang Wang, Angelika Burschinski, Kristina Schestag, Myrto T. Samara, and Stefan Leucht. 2023. “A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia.” European Archives of Psychiatry and Clinical Neuroscience 274 (4): 917–928. https://doi.org/10.1007/s00406-023-01654-2.

Harvard

Dong, S. et al. (2023) ‘A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia’, European Archives of Psychiatry and Clinical Neuroscience, 274(4), pp. 917–928. doi:10.1007/s00406-023-01654-2.

IEEE

S. Dong et al., “A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 274, no. 4, pp. 917–928, 2023, doi: 10.1007/s00406-023-01654-2.

BibTeX

@article{dong2023network,
  title     = {{A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia}},
  author    = {Dong, Shimeng and Schneider‐Thoma, Johannes and Bighelli, Irene and Siafis, Spyridon and Wang, Dongfang and Burschinski, Angelika and Schestag, Kristina and Samara, Myrto T. and Leucht, Stefan},
  journal   = {European Archives of Psychiatry and Clinical Neuroscience},
  year      = {2023},
  volume    = {274},
  number    = {4},
  pages     = {917--928},
  doi       = {10.1007/s00406-023-01654-2},
  url       = {https://doi.org/10.1007/s00406-023-01654-2}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20242323
20252424
20263131

Its field-weighted citation impact is 2.61: it has been cited 2.61 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • treatment-resistant schizophrenia
  • antipsychotic drugs
  • clozapine
  • olanzapine
  • risperidone
  • haloperidol
  • fluphenazine
  • sertindole

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Dong, S., Schneider‐Thoma, J., Bighelli, I., Siafis, S., Wang, D., Burschinski, A., Schestag, K., Samara, M. T., & Leucht, S. (2023). A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 274(4), 917–928. https://doi.org/10.1007/s00406-023-01654-2

How many times has this paper been cited?

78 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Archives of Psychiatry and Clinical Neuroscience: sign in and open the PDF from this page.

Who wrote this paper?

Shimeng Dong, Johannes Schneider‐Thoma, Irene Bighelli, Spyridon Siafis, Dongfang Wang, Angelika Burschinski, Kristina Schestag, Myrto T. Samara, Stefan Leucht.

What is the DOI of this paper?

10.1007/s00406-023-01654-2, permanently at https://doi.org/10.1007/s00406-023-01654-2. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.